Medicago and GSK’s plant based Covid-19 vaccine candidate show promise in Phase 3 trials
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
The Uteshiya facility, licensed by Healthium, will exclusively manufacture Healthium’s arthroscopy portfolio, including patented products in India and U.S.
The company plans to expand their capacity to meet the needs of pharma and biotech industries
It plans to add over 1000 employees over the next six months
Healtherbs helps in restoring the desired energy levels for daily activity and immunity
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
Collectively, these 10 laboratories are capable of processing about 10,000 samples in a day and deliver results within the given turnaround time
Subscribe To Our Newsletter & Stay Updated